IP Library Granted Patent US 12,048,719
Granted Patent B2
US 12,048,719 · App. 16/983,190 · Granted Jul 30, 2024

Acellular biologic composition and method of manufacture

Inventors: Timothy Ganey (Tampa, FL); Wendy W. Weston (Miami, FL); Gaëtan Jean-Robert Delcroix (Miami, FL)
Assignee: VIVEX BIOLOGICS GROUP, INC.
A61K35/50C12N5/00C12N5/0605
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,048,719
App. No.
16/983,190
Granted
Jul 30, 2024
Kind
B2
Abstract

A biological composition has a mixture of mechanically selected allogeneic biologic material derived from placental tissue. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture including non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts. The mixture is compatible with biologic function.

Claims (13)

1. An implantable cryopreserved acellular biological composition consisting of:

an acellular mixture of non-whole cellular placental tissue derived from amnion, chorion, umbilical cord, and liquid placental tissue components of mechanically selected biologic material derived and separated from placental tissue; wherein the whole cells have been removed from the placental tissue by density gradient centrifugation to form the acellular mixture; wherein the acellular mixture consists of vesicular components, active and inactive components of biological activity, cell fragments including organelle fragments, non-whole cell fractions, wherein one or more non-whole cell fractions include one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts, cellular excretions, cellular derivatives, and extracellular components, wherein the extracellular components include matrices, membranes, particles, and non-cellular materials derived from the placental tissue; and wherein the acellular mixture is compatible with biologic function to support new tissue formed independent of mesenchymal cells; and

a volume of polyampholyte cryoprotectant configured for direct implantation, wherein the volume of polyampholyte cryoprotectant is added to the acellular mixture prior to freezing and cryopreservation, thereby forming a suspension of the acellular mixture to a predetermined concentration in the cryoprotectant, wherein the suspension of, the acellular mixture is frozen for cryopreservation, creating a frozen cryopreserved composition configured to be thawed at the time of use.

2. The implantable cryopreserved acellular biological composition of claim 1 wherein the combination of non-whole cell components with a select number of the non-whole cell fractions sustains pluripotency in host cells.

3. The implantable cryopreserved acellular biological composition of claim 1 wherein the biological composition demonstrates and supports elaboration of active volume or spatial geometry consistent in morphology with that of endogenous tissue in the patient upon implantation.

4. The implantable cryopreserved acellular biological composition of claim 1 wherein the biological composition extends tissue regeneration that compliments or mimics host tissue complexity to be repaired.

5. The implantable cryopreserved acellular biological composition of claim 4 wherein the tissue regeneration occurs in the presence or absence of a refractory response.

6. The implantable cryopreserved acellular biological composition of claim 1 wherein the cryoprotectant creates a physical, electrical, or chemical gradient, or combination thereof, for tissue regeneration.

7. The implantable cryopreserved acellular biological composition of claim 6 wherein the gradient has a physical characteristic of modulus or topography such as charge density, field shape, or cryo or chemo toxic tendencies.

8. The implantable cryopreserved acellular biological composition of claim 1 , wherein the mixture of non-whole cell components which is derived from placental tissue has enhanced properties, including one or more of responsive molecular coupling, neutralizing inflammation, or balancing tissue stimulation for repair.

9. The implantable cryopreserved acellular biological composition of claim 1 , wherein the cryopreservation occurs at a temperature that is sub-freezing.

10. The implantable cryopreserved acellular biological composition of claim 9 wherein the cryopreservation temperature is from 0 degrees C. to −200 degrees C.

11. The implantable cryopreserved acellular biological composition of claim 1 wherein the acellular mixture is freeze-dried and the freeze-dried mixture is maintained at ambient temperature prior to adding the polyampholyte cryoprotectant.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2022
From: GANEY, TIMOTHY; WESTON, WENDY W.; DELCROIX, GAETAN JEAN-ROBERT
To: VIVEX BIOMEDICAL, INC.
Reel/Frame 062125/0952 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2022
From: VIVEX BIOMEDICAL, INC.
To: VIVEX BIOLOGICS, INC.
Reel/Frame 062126/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2022
From: VIVEX BIOLOGICS, INC.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 062126/0372 →
SECURITY INTEREST Recorded Aug 4, 2022
From: VIVEX BIOLOGICS GROUP, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 061084/0607 →